Semaglutide dose may matter more than weight loss for heart health
A large real-world study suggests semaglutide’s cardiovascular benefits may be more closely linked to the dose patients receive…
Gut microbes emerge as potential players in estrogen-driven cancers
Scientists say gut microbes may do more than recycle estrogen, but turning the endocrine-microbiome axis into a cancer…
The next goal for weight loss drugs? Fewer injections
For millions of people taking weight loss drugs, the next breakthrough may not be more weight loss. It…
People judge weight loss more harshly when GLP-1 drugs are involved, study finds
Even when medication is paired with diet and exercise, people may still feel their weight loss is less…
Genetic modification enhances “living drugs” for blood cancers
CAR T cells are patient-derived, genetically engineered immune cells. They are “living drugs” and constitute a milestone in…
Genetic study shows dual GIPR/GLP1R action curbs binge alcohol use
New genetic evidence suggests that targeting GIPR and GLP1R could reduce harmful drinking patterns while improving liver and…
Genetic variants mimicking IL-6 inhibition linked to lower cardiovascular risk
People with lower interleukin-6 activity have a reduced risk of cardiovascular diseases, a new LMU study reveals. Lowering…
Genetic variants influencing vitamin D synthesis, metabolism, and transport
From skin tone to rare mutations, scientists uncover how your genes influence vitamin D levels, and why standard…